Abstract
Cystic neoplasms of the pancreas account for about 10% of pancreatic tumors. Intraductal papillary mucinous neoplasms (IPMNs) are the most common cystic tumors of the pancreas presenting with no or unspecific clinical symptoms. Diagnosis of IPMNs is challenging and accomplished by CT, MRI, MRCP and EUS. Primarily, IPMNs are regarded as benign cystic lesions, however, almost 60% of resected IPMNs reveal malignant or invasive growth. The risk to progress to malignancy varies between 20-90% strongly depending on the origin of the lesion (main-duct type, branch-duct type) and clinico-pathological characteristics. Recently, first standardized algorithms for the treatment of IPMNs have been formulated, however, therapeutic consequences (surgical approach vs. surveillance strategy) are still controversial. This review provides a detailed overview of the currently discussed options for diagnostics, therapy and surveillance of IPMNs.
Keywords: IPMN, cystic lesions of the pancreas, precursor of pancreatic cancer, pancreatic cancer
Current Cancer Therapy Reviews
Title: Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer
Volume: 6 Issue: 3
Author(s): Albrecht Neesse, Patrick Michl, Marc Kalinowski, Peter J. Barth, Detlef K. Bartsch, Volker Ellenrieder and Thomas M. Gress
Affiliation:
Keywords: IPMN, cystic lesions of the pancreas, precursor of pancreatic cancer, pancreatic cancer
Abstract: Cystic neoplasms of the pancreas account for about 10% of pancreatic tumors. Intraductal papillary mucinous neoplasms (IPMNs) are the most common cystic tumors of the pancreas presenting with no or unspecific clinical symptoms. Diagnosis of IPMNs is challenging and accomplished by CT, MRI, MRCP and EUS. Primarily, IPMNs are regarded as benign cystic lesions, however, almost 60% of resected IPMNs reveal malignant or invasive growth. The risk to progress to malignancy varies between 20-90% strongly depending on the origin of the lesion (main-duct type, branch-duct type) and clinico-pathological characteristics. Recently, first standardized algorithms for the treatment of IPMNs have been formulated, however, therapeutic consequences (surgical approach vs. surveillance strategy) are still controversial. This review provides a detailed overview of the currently discussed options for diagnostics, therapy and surveillance of IPMNs.
Export Options
About this article
Cite this article as:
Neesse Albrecht, Michl Patrick, Kalinowski Marc, J. Barth Peter, K. Bartsch Detlef, Ellenrieder Volker and M. Gress Thomas, Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698197
DOI https://dx.doi.org/10.2174/157339410791698197 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Molecular Basis of Bicarbonate Membrane Transport in the Male Reproductive Tract
Current Medicinal Chemistry Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Molecular Pathogenesis of Pancreatic Cancer: Advances and Challenges
Current Molecular Medicine Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Ras-Induced Senescence and its Physiological Relevance in Cancer
Current Cancer Drug Targets The Future of Diabetes Management by Healthy Probiotic Microorganisms
Current Diabetes Reviews Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma
Current Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen
Current Drug Targets